Abstract：【Objective】To investigate the relationship of leptin and N-Cadherin protein expression with clinicopathological features in colorectal cancer. 【Methods】The expression of leptin and N-Cadherin protein was evaluated by immunohistochemistry in 120 cases of colorectal cancer. The relationship between the staining pattern and clinicopathogical features was analyzed.【Results】The positive rates of leptin and N-Cadherin protein in colorectal cancer were 75.8% (91/120) and 68.3%(82/120), respectively. The expression intensity of leptin and N-Cadherin protein was related to invasive depth, TNM stages, lymph node metastasis and tumor differentiation of colorectal cancer. The difference was statistically significant (P<0.05). In colorectal cancer tissues, the leptin expression was positively correlated with N-Cadherin expression; and the difference was statistically significant (P<0.001).【Conclusion】Leptin and N-Cadherin may play an important role in the occurrence and development of colorectal cancer. The detection of leptin and N-Cadherin may be helpful for the evaluation of prognosis and treatment for colorectal cancer patients.
李美玲, 刘红兵, 张海明, 汪砥. 瘦素、N-Cadherin在大肠癌中的表达及临床意义*[J]. 医学临床研究, 2021, 38(1): 58-60.
LI Mei-lin, LIU Hong-bin, ZHANG Hai-ming, et al. Expression and Clinicopathological Significance of Leptin and N-Cadherin Expression in Patients with Colorectal Cancer. JOURNAL OF CLINICAL RESEARCH, 2021, 38(1): 58-60.
[1] Brody H.Colorectal cancer[J].Nature,2015, 521(7551):S1. [2] Gupta N, Kupfer SS, Davis AM.Colorectal cancer screening[J].JAMA,2019, 321(20): 2022-2023. [3] Pardamean B, Baurley JW, Pardamean CI, et al. Changing colorectal cancer trends in Asians[J].Int J Colorectal Dis,2016, 31(8):1537-1538. [4] Zhang Y, Chua S Jr.Leptin function and regulation[J].Compr Physiol,2017, 8(1):351-369. [5] Paz-Filho G, Mastronardi CA, Licinio J.Leptin treatment: facts and expectations[J].Metabolism,2015, 64(1):146-156. [6] Olea-Flores M, Juárez-Cruz JC, Mendoza-Catalán MA, et al. Signaling pathways induced by leptin during epithelial?mesenchymal transition in breast cancer[J].Int J Mol Sci,2018, 19(11): 3493. [7] 汪砥,陈健,陈辉,等. 瘦素与p-mTOR在大肠癌中的表达及临床意义[J].中南大学学报(医学版),2012,37(3):233-237. [8] Derghal A, Astier J, Sicard F, et al. Leptin modulates the expression of miRNAs-targeting POMC mRNA by the JAK2-STAT3 and PI3K-Akt pathways[J].J Clin Med,2019, 8(12):2213. [9] Garcia-Galiano D, Borges BC, Allen SJ, et al. PI3K signalling in leptin receptor cells: Role in growth and reproduction[J].J Neuroendocrinol,2019, 31(5):e12685. [10] Robb VA, Karbowniczek M, Klein-Szanto AJ, et al. Activation of the mTOR signaling pathway in renal clear cell carcinoma[J].J Urol,2007,177(1):346-352. [11] Shaw RJ, Cantley LC.Ras, PIK and mTOR signalling controls tumour cell growth[J].Nature,2006, 441(7092):424-430. [12] Campbell L, Jasani B, Edwards K, et al. Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma[J].Br J Cancer,2008, 98(5):931-940. [13] Loh CY.The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges[J].Cells,2019, 8(10): 1118. [14] Dong P, Xiong Y, Yue J, et al. Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion[J].Front Oncol,2018, 8:386. [15] Blaschuk OW.N-cadherin antagonists as oncology therapeutics[J].Philos Trans R Soc Lond B Biol Sci,2015, 370(1661):20140039.
2021, Vol. 38 
